Takeda Pharmaceuticals America Inc., a subsidiary of the global biopharmaceutical company Takeda Pharmaceutical Company Limited, is the prime contractor on this General Services Administration (GSA) Indefinite Delivery Vehicle (IDV) contract to provide a range of specialty pharmaceutical products to various U.S. government agencies, including the Department of Veterans Affairs (VA), Department of Justice Bureau of Prisons, and Department of Defense.
The contract, which has a ceiling value of $719,535,960, covers the supply of critical medications used to treat conditions such as rare diseases, hemophilia, immune deficiencies, hereditary angioedema, short bowel syndrome, hypocalcemia, and cancer. Key products include CINRYZE, KALBITOR, GATTEX, NATPARA, ADVATE, GAMMAGARD, FEIBA, and TAKHZYRO. The contract does not utilize any set-aside designations, as the specialized nature of the pharmaceutical products precludes their use. Deliveries are predominantly to VA medical centers, federal correctional institutions, and military facilities across the United States, with firm fixed-price delivery orders ranging from $14,000 to over $490,000. Additionally, Takeda holds a $19.4 million Blanket Purchase Agreement with the VA National Acquisition Center to streamline the procurement of these critical specialty medications over a 4-year period.
Generated 1/15/25, 9:15 AM